Roger M. Boissonneault Chief Executive Officer, President and Director
Roger M. Boissonneault, Chief Executive Officer, President and Director, was appointed President and Director of the Company as of January 5, 2005.
Mr. Boissonneault was appointed Chief Executive Officer and Director for Warner Chilcott PLC (the predecessor of the Company) in September 2000.
He previously served as President and Chief Operating Officer of Warner Chilcott PLC (the predecessor company acquired by Warner Chilcott PLC in
September 2000) from 1996 to 2000, serving as a director from 1998 through 2000. From 1976 to 1996 Mr. Boissonneault served in various capacities with
Warner-Lambert, including Vice President, Female Healthcare, Director of Corporate Strategic Planning, and Director of Obstetrics/Gynecology Marketing.
W. Carlton Reichel President, Pharmaceuticals
W. Carl Reichel, President, Pharmaceuticals, joined Warner Chilcott PLC (the predecessor of the Company) as President in October
2000 after nearly 20 years of experience at Parke-Davis, a division of Warner-Lambert (now a part of Pfizer), where he, together with
Mr. Boissonneault, was a pioneer in the pharmaceutical marketing methods currently employed by us. Most recently, he held the position
of President, U.K./British Isles at Warner-Lambert.
Anthony D. Bruno Executive Vice President, Corporate Development
Anthony D. Bruno, Executive Vice President, Corporate Development, joined Warner Chilcott PLC (the predecessor of the Company) in
March 2001 as Senior Vice President, Corporate Development and General Counsel. Mr. Bruno was promoted to Executive Vice President
in April 2003 and continued to serve as General Counsel of the Company until August 1, 2005. Prior to joining the Company, Mr. Bruno spent
17 years with Warner-Lambert where his most recent position was Vice President and Associate General Counsel, Pharmaceuticals, and
he was responsible for all legal matters relating to Warner-Lambert's pharmaceutical business worldwide.
Paul Herendeen Executive Vice President and Chief Financial Officer
Paul Herendeen, Executive Vice President and Chief Financial Officer, joined Warner Chilcott in this position on April 1, 2005 and is
responsible for our finance, accounting, treasury and management information system functions. Prior to joining Warner Chilcott,
Mr. Herendeen was Executive Vice President and Chief Financial Officer of MedPointe Inc. From 1998 through March 2001, Mr. Herendeen
served as Executive Vice President and Chief Financial Officer of the predecessor company acquired by Warner Chilcott PLC
in September 2000. Mr. Herendeen also served as a director of Warner Chilcott PLC from October 2000 through March 2001.
Leland H. Cross Senior Vice President, Technical Operations
Leland H. Cross, Senior Vice President, Technical Operations, joined Warner Chilcott PLC (the predecessor of the Company) in this
position on September 1, 2001 and is responsible for our technical operations worldwide. From 1994 to
2001, Mr. Cross was part of the Global Manufacturing group at Warner-Lambert (which became part of
Pfizer in June 2000), where most recently he was General Manager of Pfizer Ireland Pharmaceuticals,
responsible for Pfizer's dosage manufacturing operations in Ireland. Prior to joining Warner-Lambert,
Mr. Cross managed a manufacturing operation for Merck & Co. Inc.
Herman Ellman M.D. Senior Vice President, Clinical Development
Herman Ellman, M.D., Senior Vice President, Clinical Development, joined Warner Chilcott PLC (the predecessor of the Company) in
this position in June 2000. Dr. Ellman is responsible for clinical development and medical affairs
activities. Prior to joining Warner Chilcott PLC, Dr. Ellman held the position of Medical Director for
Women's Healthcare of Berlex Laboratories.
Izumi Hara Senior Vice President, General Counsel and Corporate Secretary
Izumi Hara, Senior Vice President, General Counsel and Corporate Secretary, joined Warner Chilcott PLC (the predecessor of the Company)
as Senior Vice President and Deputy General Counsel in June 2001 and is responsible
for the legal matters of the Company. She was promoted to General Counsel as of August 1, 2005.
Prior to joining Warner Chilcott PLC, Ms. Hara held positions of increasing responsibility at Warner-
Lambert where her most recent position was Vice President and Associate General Counsel,
Corporate Affairs, where she was responsible for all corporate legal matters, including acquisitions,
divestitures, alliances and other transactions in all of Warner-Lambert's lines of business worldwide.
Alvin Howard Senior Vice President, Regulatory Affairs
Alvin D. Howard, Senior Vice President, Regulatory Affairs, joined Warner Chilcott PLC (the predecessor of the Company) as Vice
President, Regulatory Affairs in February 2001. He was promoted to Senior Vice President as of
August 1, 2005 and is responsible for the registration of all of our products and for managing our
relationships with the FDA, Health Canada and other agencies regulating the sale of pharmaceutical
products. Prior to joining the Company, Mr. Howard was Vice President, Worldwide Regulatory Affairs
at Roberts Pharmaceuticals.
Stock Information
NASD:WCRX
$17.23+ 0.26
May 13, 2008
4:14 PM ET
Quotes delayed by approximately 20 minutes. Information provided by TurboFeed.